
Cramer’s Morning Take: Eli Lilly 11/24/25
Squawk on the Street
00:00
Novo Nordisk Alzheimer's Trial Disappoints
Jim Cramer introduces disappointing two-year GLP-1 Alzheimer’s trial results from Novo Nordisk and market reaction.
Play episode from 01:02
Transcript


